Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Aciphex, adjunctive, agonist, ASC, authoritative, BID, cimetidine, Codification, comment, compelling, Cymbalta, Depomed, depreciation, duloxatine, esomeprazole, examine, famotidine, GR, healing, hearing, heartburn, hydrochloride, implementing, lansoprazole, lawsuit, lumbar, maintenance, mitigation, muscle, Mylan, NAM, neurologicial, Nexium, nizatidine, omeprazole, pantoprazole, PPI, Prevacid, Prilosec, proceed, proton, Protonix, pump, rabeprazole, ranitidine, rash, receptor, reduction, region, Regurgitation, Reinvestment, RequipXL, residual, Roxane, secondary, Seika, skin, Sumitomo, symptomatic, theAmerican, titration, Topamax, Topic, transdermal, uncomfortable, undergo, vendor, wake, zoster
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.35 Amended and Restated Distribution and License Agreement
- 31.1 Certification of the CEO Pursuant to Rules 13A-14(A) and 15D-14(A)
- 31.2 Certification of the CFO Pursuant to Rules 13A-14(A) and 15D-14(A)
- 32.1 Certification of CEO and CFO Required by Rule 13A-14(B) or Rule 15D-14(B)
Related press release
XNPT similar filings
Filing view
External links